磷酸盐特异性饮食治疗对维持性血液透析成人血磷水平的影响:系统综述与Meta分析
该系统综述与Meta分析检索2000年1月至2019年11月的对照试验,纳入12项临床试验(11项随机、1项非随机),评估营养师提供的磷酸盐特异性饮食治疗对血液透析患者血磷的影响。饮食治疗在所有研究中均降低血磷,8项研究达统计学显著;每月20-30分钟饮食治疗可使持续性高磷血症患者4-6个月内血磷显著下降且不影响营养状态,但证据质量低。
要点
- 每月20-30分钟营养师饮食治疗可显著降低持续性高磷血症患者血磷,均差-0.87 mg/dl。
- 该饮食治疗不损害营养状态,但停药后似难以维持降磷效果。
- 总体证据质量低,主要因随机化问题及方案偏离。
核心结论
- 低质量证据表明,营养师每月饮食治疗对血液透析患者持续性高磷血症可能是安全有效的治疗。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、Embase、CINAHL、Web of Science、Cochrane Central Register of Controlled Trials等数据库2000年1月至2019年11月英文对照试验。
- 共纳入12项临床试验(11项随机、1项非随机),评估营养师提供的磷酸盐特异性饮食治疗对血液透析患者血磷的影响。
- 采用GRADE方法评估偏倚风险与证据确定性。
主要发现
- 饮食治疗在所有研究中均降低血磷,其中8项研究达统计学显著。
- 每月20-30分钟饮食治疗使持续性高磷血症4-6个月的患者血磷显著降低(均差-0.87 mg/dl;95%CI -1.40至-0.33 mg/dl),且不损害营养状态。
- 若停止饮食治疗,似难以维持降磷效果。
关键数值与推荐
- 每月20-30分钟饮食治疗使血磷均差-0.87 mg/dl(95%CI -1.40至-0.33 mg/dl)。
- 总体证据确定性低,主要因随机化问题及方案偏离。
临床怎么用
- 对维持性血液透析伴持续性高磷血症患者,可考虑由营养师提供每月20-30分钟的磷酸盐特异性饮食治疗。
- 需注意停药后降磷效果可能难以维持,应持续管理。
局限性
- 试验设计、设置和方法差异过大,无法适当合并进行Meta分析。
- 试验数量有限,无法评估磷酸盐特异性饮食治疗的时机、剂量和策略。
- 总体证据质量低,主要因随机化问题及方案偏离。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Hyperphosphatemia is a persistent problem in individuals undergoing maintenance hemodialysis, which may contribute to vascular and bone complications. In some dialysis centers, dietitians work with patients to help them manage serum phosphate. Given the regularity of hyperphosphatemia in this population and constraints on kidney dietitian time, the authors aimed to evaluate the evidence for this practice. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: There was a systematic review and meta-analysis of clinical trials. MEDLINE, Embase, CINAHL, Web of Science, Cochrane Central Register of Controlled Trials, and other databases were searched for controlled trials published from January 2000 until November 2019 in the English language. Included studies were required to examine the effect of phosphate-specific diet therapy provided by a dietitian on serum phosphate in individuals on hemodialysis. Risk of bias and certainty of evidence were assessed using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) method. RESULTS: Of the 8054 titles/abstracts identified, 168 articles were reviewed, and 12 clinical trials (11 randomized, one nonrandomized) were included. Diet therapy reduced serum phosphate compared with controls in all studies, reaching statistical significance in eight studies, although overall certainty of evidence was low, primarily due to randomization issues and deviations from protocol. Monthly diet therapy (20-30 minutes) significantly lowered serum phosphate in patients with persistent hyperphosphatemia for 4-6 months, without compromising nutrition status (mean difference, -0.87 mg/dl; 95% confidence interval, -1.40 to -0.33 mg/dl), but appeared unlikely to maintain these effects if discontinued. Unfortunately, trials were too varied in design, setting, and approach to appropriately pool in meta-analysis, and were too limited in number to evaluate the timing, dose, and strategy of phosphate-specific diet therapy. CONCLUSIONS: There is low-quality evidence that monthly diet therapy by a dietitian appears to be a safe and efficacious treatment for persistent hyperphosphatemia in patients on HD.
引用
- St-Jules DE, Rozga MR, Handu D, et al. Effect of Phosphate-Specific Diet Therapy on Phosphate Levels in Adults Undergoing Maintenance Hemodialysis: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol. 2020. PMID: 33380474. doi:10.2215/CJN.09360620
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。